HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Abstract Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline...

Full description

Bibliographic Details
Main Authors: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00434-w

Internet

https://doi.org/10.1038/s41523-022-00434-w

Similar Items